Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Lynde

Showing results (91-100 of 141) with videos related to

Pageof 15
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|December 10, 2025
Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasisJoseph F Merola, Lyn Guenther, Charles Lynde, et al.
Journal of the American Academy of Dermatology|June 4, 2018
Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension studyChristos C Zouboulis, Martin M Okun, Errol P Prens, et al.
Dermatology and Therapy|March 28, 2024
Maintenance of Investigator's Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic DermatitisLawrence F Eichenfield, Linda F Stein Gold, Charles Lynde, et al.
Advances in Therapy|December 14, 2022
Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World SettingCharles Lynde, Elisabeth Riedl, Julia-Tatjana Maul, et al.
Journal of Drugs in Dermatology : JDD|January 6, 2025
INDIVIDUAL ARTICLE: Real-World Cases of Clascoterone Topical Treatment for Acne and Related DisordersCharles Lynde, Sonya Abdulla, Anneke Andriessen, et al.
American Journal of Clinical Dermatology|March 27, 2020
Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)Joel Schlessinger, Julie S Shepard, Richard Gower, et al.
Journal of the American Academy of Dermatology|April 19, 2023
Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: A Canadian perspectiveJensen Yeung, Melinda J Gooderham, H Chih-Ho Hong, et al.
JAAD International|November 24, 2021
Identifying gaps and providing recommendations to address shortcomings in the investigation of acne sequelae by the Personalising Acne: Consensus of Experts panelAlison Layton, Andrew Alexis, Hilary Baldwin, et al.
American Journal of Clinical Dermatology|January 14, 2026
Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP)Christopher G Bunick, Nina Magnolo, Angela Moore, et al.
Journal of Drugs in Dermatology : JDD|January 22, 2015
Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trialsLinda Stein Gold, Leon Kircik, Joseph Fowler, et al.
Pageof 15

Showing results (91-100 of 141) with videos related to

Sort By:
Pageof 15
Journal of the European Academy of Dermatology and Venereology : JEADV|December 10, 2025
Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasisJoseph F Merola, Lyn Guenther, Charles Lynde, et al.
Journal of the American Academy of Dermatology|June 4, 2018
Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension studyChristos C Zouboulis, Martin M Okun, Errol P Prens, et al.
Dermatology and Therapy|March 28, 2024
Maintenance of Investigator's Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic DermatitisLawrence F Eichenfield, Linda F Stein Gold, Charles Lynde, et al.
Advances in Therapy|December 14, 2022
Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World SettingCharles Lynde, Elisabeth Riedl, Julia-Tatjana Maul, et al.
Journal of Drugs in Dermatology : JDD|January 6, 2025
INDIVIDUAL ARTICLE: Real-World Cases of Clascoterone Topical Treatment for Acne and Related DisordersCharles Lynde, Sonya Abdulla, Anneke Andriessen, et al.
American Journal of Clinical Dermatology|March 27, 2020
Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)Joel Schlessinger, Julie S Shepard, Richard Gower, et al.
Journal of the American Academy of Dermatology|April 19, 2023
Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: A Canadian perspectiveJensen Yeung, Melinda J Gooderham, H Chih-Ho Hong, et al.
JAAD International|November 24, 2021
Identifying gaps and providing recommendations to address shortcomings in the investigation of acne sequelae by the Personalising Acne: Consensus of Experts panelAlison Layton, Andrew Alexis, Hilary Baldwin, et al.
American Journal of Clinical Dermatology|January 14, 2026
Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP)Christopher G Bunick, Nina Magnolo, Angela Moore, et al.
Journal of Drugs in Dermatology : JDD|January 22, 2015
Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trialsLinda Stein Gold, Leon Kircik, Joseph Fowler, et al.
Pageof 15